Blog

At the third plenary at this year's North American Cystic Fibrosis Conference, we explored what it means to partner in care and how to do it better.

Finding a way to reduce lung inflammation in cystic fibrosis has challenged researchers, but we have made important advances in our understanding of this CF complication in just the last few years. Several drugs also are in development to fight another complication -- the inability to clear mucus from the lungs.

As a mother of two children with cystic fibrosis, I am glad to hear that the Cystic Fibrosis Foundation is launching the Infection Research Initiative to address the chronic infections that dramatically impact the lives of people with CF.

Reflecting the continued momentum we're making in the fight against cystic fibrosis, the latest Patient Registry data show steady gains in survival for people with CF. With this good news comes a lot of excitement, along with some questions.

The video of the second plenary at this year's North American Cystic Fibrosis Conference was focused on lung transplantation and is now available to watch online. Having had a lung transplant and as one of the people with CF featured in the video, this particular session had a personal meaning for me.

This year, theratyping, the process of matching medications with mutations, enabled more people with cystic fibrosis who have rare mutations to benefit from modulators. In the first plenary at the NACFC, we heard more about how theratyping will be used, as well as other future advances coming in CF treatment.